https://scholars.lib.ntu.edu.tw/handle/123456789/494883
Title: | Opportunities of circulating tumor DNA in lung cancer | Authors: | Wu T.-H Hsiue E.H.-C CHIH-HSIN YANG |
Keywords: | ctDNA; Early detection; Immune checkpoint blockade; Lung cancer; Targeted therapy | Issue Date: | 2019 | Publisher: | W.B. Saunders Ltd | Journal Volume: | 78 | Start page/Pages: | 31-41 | Source: | Cancer Treatment Reviews | Abstract: | Current classification and treatment of lung cancer rely increasingly on molecular and genetic testing. Obtaining tumor tissue is not always feasible and multiple biopsies are undesirable. In response to the demand for non-invasive molecular and genetic testing in cancer care, several liquid biopsy technologies, including circulating DNA (ctDNA), have been developed. ctDNA analysis is now technically feasible to be carried out in large scales and integrated into clinical practice owing to the advances in technology. Despite the challenges in improving test accuracy and cost-effectiveness, there are huge potentials for ctDNA analysis in lung cancer management. This review focuses on the clinical utility of ctDNA analysis in lung cancer, including early detection, monitoring treatment response and detecting residual disease, identification of genetic determinants for targeted therapy, and predicting efficacy of immune checkpoint blockade. ? 2019 Elsevier Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069491269&doi=10.1016%2fj.ctrv.2019.07.002&partnerID=40&md5=9996edcf2a276329a01607ff642e099b https://scholars.lib.ntu.edu.tw/handle/123456789/494883 |
ISSN: | 0305-7372 | DOI: | 10.1016/j.ctrv.2019.07.002 | SDG/Keyword: | alectinib; atezolizumab; brigatinib; ceritinib; checkpoint kinase inhibitor; circulating tumor DNA; crizotinib; docetaxel; epidermal growth factor receptor; erlotinib; gemcitabine; loratinib; nivolumab; pembrolizumab; unclassified drug; circulating tumor DNA; DNA; tumor marker; cancer prognosis; clinical practice; cost effectiveness analysis; diagnostic accuracy; disease management; DNA determination; drug approval; drug efficacy; early cancer diagnosis; EGFR gene; gene mutation; genetic analysis; human; liquid biopsy; lung cancer; minimal residual disease; molecularly targeted therapy; non small cell lung cancer; patient monitoring; prediction; Review; small cell lung cancer; treatment response; blood; lung tumor; Biomarkers, Tumor; Circulating Tumor DNA; DNA, Neoplasm; Humans; Liquid Biopsy; Lung Neoplasms |
Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.